How to appeal an Aetna pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Cited policy: Aetna Clinical Policy Bulletin Tumor Necrosis Factor Antagonists + CPB on Ustekinumab (Stelara) and Vedolizumab (Entyvio) — pediatric IBD indications

NASPGHAN IBD Guideline: biologic for moderate-severe pediatric Crohn's / UC, top-down approach for aggressive disease (deep ulcers, perianal, growth failure, EIM); FDA on-label peds age; peds GI prescribing.

How Aetna denies pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology — and how to counter it

Where Aetna pushes back: 1) Step therapy through 5-ASA / steroids / immunomodulators not exhausted; 2) Top-down approach 'experimental'; 3) FDA peds age cutoff issue.

Counter-arguments that hold up: Cite NASPGHAN IBD Guideline (Rosen IBD 2014; updated). REACH (Hyams Gastroenterology 2007) for infliximab peds Crohn's; IMAgINE (Hyams 2012) adalimumab peds Crohn's. FDA approvals: Remicade peds Crohn's >=6, Humira peds Crohn's >=6, Stelara peds Crohn's >=6 (recent expansion), Entyvio peds expansion. Document growth failure + Pediatric Crohn's Disease Activity Index (PCDAI) + endoscopic disease + EIMs (perianal, EIM).

What Aetna typically denies for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Peds congenital heart surgery
• Kawasaki workup + IVIG
• Pediatric ECMO
• Peds EoE workup + therapy
• Peds IBD biologic
• Peds asthma biologic / admission

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.